Acceleron Pharma Inc (NASDAQ:XLRN): Stock Sentiment

April 17, 2018 - By Maria Brooks

Acceleron Pharma Inc. (NASDAQ:XLRN) Logo

Sentiment for Acceleron Pharma Inc (NASDAQ:XLRN)

Acceleron Pharma Inc (NASDAQ:XLRN) institutional sentiment decreased to 1.09 in 2017 Q4. Its down -0.72, from 1.81 in 2017Q3. The ratio has dropped, as 61 investment professionals increased and started new equity positions, while 56 sold and decreased their equity positions in Acceleron Pharma Inc. The investment professionals in our partner’s database now hold: 38.14 million shares, up from 37.73 million shares in 2017Q3. Also, the number of investment professionals holding Acceleron Pharma Inc in their top 10 equity positions was flat from 3 to 3 for the same number . Sold All: 24 Reduced: 32 Increased: 47 New Position: 14.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.74 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

The stock increased 1.23% or $0.46 during the last trading session, reaching $37.94. About 136,910 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 45.87% since April 17, 2017 and is uptrending. It has outperformed by 34.32% the S&P500.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on May, 14. They expect $-0.64 EPS, up 3.03 % or $0.02 from last year’s $-0.66 per share. After $-0.62 actual EPS reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts 3.23 % negative EPS growth.

Sectoral Asset Management Inc holds 3.78% of its portfolio in Acceleron Pharma Inc. for 712,356 shares. Foresite Capital Management Ii Llc owns 244,756 shares or 3.63% of their US portfolio. Moreover, Perceptive Advisors Llc has 2.27% invested in the company for 1.62 million shares. The New York-based Ghost Tree Capital Llc has invested 1.99% in the stock. Hamilton Lane Advisors Llc, a Pennsylvania-based fund reported 69,503 shares.#img1#

Since January 1, 0001, it had 0 buys, and 13 selling transactions for $7.84 million activity.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Ratings analysis reveals 83% of Acceleron Pharma’s analysts are positive. Out of 6 Wall Street analysts rating Acceleron Pharma, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $44.0 while the high is $63. The stock’s average target of $51.17 is 34.87% above today’s ($37.94) share price. XLRN was included in 8 notes of analysts from November 2, 2017. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Overweight” rating by Barclays Capital on Wednesday, February 28. RBC Capital Markets maintained the stock with “Hold” rating in Thursday, November 2 report. As per Tuesday, November 14, the company rating was maintained by Credit Suisse. The rating was initiated by H.C. Wainwright on Monday, January 8 with “Buy”. JP Morgan upgraded the shares of XLRN in report on Monday, February 26 to “Overweight” rating. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Buy” rating by H.C. Wainwright on Wednesday, March 28. The rating was maintained by H.C. Wainwright on Wednesday, February 28 with “Buy”. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Buy” rating given on Thursday, March 1 by Citigroup.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: